Glossier Invisible Shield Daily Sunscreen Broad Spectrum Spf 35

For general photoprotection, healthcare providers recommend the following:

• Topical Application: Apply a liberal amount (approximately 2mg/cm² of skin) to all exposed areas 15 to 30 minutes before sun exposure.
• Reapplication: Reapply at least every two hours, or more frequently after swimming, sweating, or towel drying.

• Children under 6 months: The American Academy of Pediatrics (AAP) generally recommends avoiding the use of chemical sunscreens like Avobenzone in infants under 6 months unless specifically directed by a pediatrician. Physical barriers (clothing/shade) are preferred.
• Children 6 months and older: Apply topically as directed for adults, ensuring the product does not get into the child's eyes.

Renal Impairment

No dosage adjustments are typically required for topical use in patients with kidney disease, as systemic absorption is minimal.

Hepatic Impairment

No specific adjustments are documented for topical application; however, patients with severe liver failure should consult their doctor if using large-surface-area applications daily.

Elderly Patients

Elderly patients may have thinner skin (atrophic skin), which could potentially increase systemic absorption. Use as directed, but monitor for localized skin reactions.

Avobenzone is for external use only.

1. 1Clean the skin area before application.
2. 2Apply evenly and rub in thoroughly.
3. 3Avoid contact with eyes, nostrils, and mouth.
4. 4Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F). Avoid excessive heat, as Avobenzone is photounstable and can degrade if left in a hot car or direct sunlight for extended periods.

If you forget to apply Avobenzone before going outdoors, apply it as soon as you remember. However, be aware that protection is not immediate; seek shade until the product has had time to set (approximately 15 minutes).

Topical overdose is unlikely. However, if accidental ingestion occurs, symptoms may include gastrointestinal irritation. In cases of ingestion, contact a Poison Control Center immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most individuals tolerate Avobenzone well. However, because it is a Non-Standardized Chemical Allergen, some users may experience:

• Mild Skin Irritation: Redness or a stinging sensation immediately after application.
• Contact Dermatitis: A localized itchy rash that develops within 24-48 hours of use.

• Acne Exacerbation: Some oil-based Avobenzone formulations may clog pores (comedogenic effect), leading to breakouts.
• Folliculitis: Inflammation of the hair follicles in the area of application.

• Photoallergy: A rare condition where the skin only reacts to Avobenzone when it is simultaneously exposed to sunlight.
• Urticaria (Hives): A systemic allergic response characterized by raised, itchy welts.

> Warning: Stop using Avobenzone and call your doctor immediately if you experience any of these:

• Anaphylaxis: Symptoms include swelling of the face, tongue, or throat; difficulty breathing; or severe dizziness.
• Severe Blistering: Widespread skin peeling or painful blisters (may indicate a severe hypersensitivity reaction).
• Generalized Erythroderma: Intense redness covering a large portion of the body.

Prolonged use of Avobenzone is generally considered safe. However, because Avobenzone is photounstable, its breakdown products can sometimes cause cumulative skin sensitization over many years of use. There is ongoing research into the long-term effects of systemic absorption, though no definitive clinical harm has been established as of 2024.

No FDA black box warnings have been issued for Avobenzone. It is generally recognized as safe and effective (GRASE) when used as directed for topical photoprotection.

Report any unusual symptoms to your healthcare provider.

Avobenzone is highly effective for UVA protection but requires stabilization. It should not be used on broken, damaged, or infected skin. Patients with a history of multiple chemical sensitivities should perform a 'patch test' on a small area of skin before widespread use.

No FDA black box warnings for Avobenzone.

• Allergic Reactions: As a known chemical allergen, Avobenzone is a frequent cause of cosmetic contact dermatitis. If a rash develops, discontinue use immediately.
• Ocular Irritation: Avobenzone is notorious for causing significant eye stinging. Avoid application near the eyelid margins.
• Photodegradation: Avobenzone breaks down quickly when exposed to sunlight (losing up to 36% of its effectiveness after one hour of exposure) unless it is 'photostabilized' with other ingredients like Octocrylene.

No routine blood tests are required for standard topical use. However, if a patient develops chronic dermatitis, a dermatologist may perform Patch Testing using a standardized allergen series that includes Avobenzone to confirm sensitivity.

Avobenzone does not typically interfere with the ability to drive or operate machinery.

There are no known direct interactions between topical Avobenzone and alcohol consumption.

There are no withdrawal symptoms associated with stopping Avobenzone. However, discontinuing use will immediately remove your protection against UVA radiation, increasing the risk of sunburn and long-term skin damage.

> Important: Discuss all your medical conditions with your healthcare provider before starting Avobenzone.

• Octinoxate (Ethylhexyl Methoxycinnamate): While often paired, Octinoxate can significantly accelerate the degradation of Avobenzone, rendering the UVA protection ineffective. Many modern formulations use stabilizers to prevent this, but raw mixing is discouraged.

• Mineral Sunscreens (Uncoated Zinc Oxide/Titanium Dioxide): If not properly coated, these minerals can catalyze the degradation of Avobenzone through a photocatalytic reaction, reducing the efficacy of the sunscreen.

• Topical Retinoids (Tretinoin, Adapalene): Using Avobenzone-containing products simultaneously with retinoids may increase skin sensitivity and irritation potential. It is often recommended to use retinoids at night and Avobenzone-based sunscreens during the day.

There are no known food interactions with topically applied Avobenzone. High-fat meals do not affect the absorption of topical formulations.

• St. John’s Wort: This herb is known to cause photosensitivity. Combining St. John's Wort with Avobenzone may require more frequent application of the sunscreen to prevent skin reactions.

Avobenzone is not known to interfere with standard clinical laboratory tests (e.g., CBC, Liver Function Tests).

For each major interaction, the primary concern is reduced efficacy (photodegradation) rather than systemic toxicity. Management strategies include using products that are specifically formulated to be 'photostable' and avoiding the mixing of different sunscreen brands on the skin at the same time.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Hypersensitivity: Avobenzone must NEVER be used in individuals with a known, documented allergy to butyl methoxydibenzoylmethane or other dibenzoylmethane derivatives. Exposure can lead to severe contact dermatitis or anaphylaxis.
• Broken or Denuded Skin: Do not apply to skin with open wounds, severe burns, or active infections, as this significantly increases the risk of systemic absorption and localized irritation.

• Eczema/Atopic Dermatitis: Patients with active eczema flares may find Avobenzone irritating and should consult a dermatologist for a physical-blocker alternative (like Zinc Oxide).
• Rosacea: The chemical nature of Avobenzone can trigger flushing in sensitive rosacea patients.

Patients who react to Avobenzone may also show cross-sensitivity to other chemical UV filters, particularly Isopropyldibenzoylmethane. Always check ingredient labels for related chemical names.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Avobenzone.

FDA Pregnancy Category: Not formally assigned for topical sunscreens, but generally considered acceptable.

• Data: Studies on pregnant women are limited, but systemic absorption is low. However, some animal studies have explored endocrine-disrupting potential at very high systemic doses. Most clinicians agree that the benefit of preventing skin cancer outweighs the theoretical risks.

Avobenzone has been detected in human breast milk in trace amounts following heavy topical use. However, the clinical significance for the nursing infant is unknown. To minimize exposure, avoid applying Avobenzone directly to the nipple area before breastfeeding.

Approved for use in children over 6 months of age. Because children have a higher surface-area-to-body-mass ratio, they may absorb more of the chemical systemically. Use with caution and emphasize physical shading.

No specific restrictions for the elderly. However, older patients should be monitored for skin thinning and increased risk of contact sensitization.

No dosage adjustments are necessary. The small amount of Avobenzone that reaches systemic circulation is unlikely to accumulate to toxic levels in patients with renal failure.

No specific data available. Use with standard caution in patients with severe hepatic dysfunction.

> Important: Special populations require individualized medical assessment.

Avobenzone acts as a UVA filter by absorbing ultraviolet radiation in the 320–400 nm range. It possesses an enol-keto tautomerism; upon UV exposure, it absorbs a photon and transitions from the chelated enol form to the unchelated diketo form. Furthermore, its classification as an Adenosine Receptor Agonist suggests it may play a role in modulating cellular signaling pathways related to inflammation and nitrogen binding.

• Onset: Protection begins as soon as the film dries on the skin (approx. 15 mins).
• Duration: Effective for approximately 2 hours of direct sun exposure before reapplication is required.
• Tolerance: No known pharmacological tolerance; however, the chemical itself degrades upon UV exposure.

| Parameter | Value |

|---|---|

| Bioavailability | <1% (Topical) |

| Protein Binding | ~95% (Systemic) |

| Half-life | 1.5 - 8 hours (Systemic) |

| Tmax | 2 - 4 hours (Post-application) |

| Metabolism | Hepatic (Glucuronidation) |

| Excretion | Renal (Primary) |

• Molecular Formula: C20H22O3
• Molecular Weight: 310.39 g/mol
• Solubility: Soluble in oils and organic solvents; insoluble in water.
• Structure: A dibenzoylmethane derivative with a methoxy and a butyl group.

Avobenzone is a Dibenzoylmethane UV Filter. It is often grouped with other organic sunscreens but stands alone as the primary organic UVA1 absorber approved in the United States.